TAC1 and migraine disorder: Treatment with a triptan, ZOL, significantly reduced the levels of pain neurotransmitters; CGRP, substance P, and NO, migraine neurogenic neuroinflammation marker; TNF-α that has a key role in migraine transition from episodic to chronic one [68], and trigeminovascular system activation marker; c-fos, compared to untreated rats with induced migraine.